Why didn't IMGN mgmt say anything in their PR about what is bad and ugly about taxanes compared to Kadcyla? Alopecia, nausea, neutropenia, infections, .....
Why is superiority in PFS the primary objective, when FDA will approve Kadcyla's use for advance mBC if comparable efficacy is demonstrated? I guess Roche wants to be able to sell a proven superior product for first line use and easily justify Kadcyla's hefty price tag.
It looks like IMGN would have been better off doing their final equity offering when pps was at $13.
I'm kind of interest in the stock. But first things first, SHARE with ME... what is their quarterly burn rate going forward?  Are they going to raise fund to dilute the outstanding shares soon? Without those insight, better stay away from IMGN! Put your money on NQ instead.
2 Ambiens does quite nicely. It appears like you're a bit worried about a short position to the point of insomnia. Just hit that buy to cover button and you'll sleep like a baby.
If the BOD has not been listening to shareholder complaints, they will now. It's time for massive change, firing Junius, inserting a turnaround CEO, cost cutting and then a sale. I wonder if Roche was not intentionally vague to crush the shares and open IMGN to a low-priced acquisition. If they would have waited until Monday to announce, it would have saved me a bundle; this was painful.
I wonder why Yahoo did not reproduce Motley Fool's very bullish comments on IMGN that came out on Friday? One can find them on the NASDAQ Website.
I think everybody is getting their pitchforks and heading to Junius's house. I don't know what to say about this? From $20 to $5 in a very short period of time. Well, at least the board cashed out in time, they always seem too be ahead of the crapstorn, don't they?
This stock with its pipeline could really be the best stock to own this year. Looks like the pipeline is full of good drugs and they will make owning essential. Next stop could be 15
Sentiment: Strong Buy
Credit Suisse Assigned $6 to Kadcyla Royalties, $7.00 Pipeline and $1 to NOL & Cash. This is an exaggerated affect due to options. It will settle in the $7-8 area after tax selling. This may actually make it more appealing to an acquirer such as Sanofi, Novartis or Amgen.
It does appear that, at least in the short run, we are headed higher. Closing at or near the high of the day, always seems to indicate that IMGN will head higher over the next 1-2 days. Yesterday does more and more look like a double bottom and I would expect IMGN to test the 6.30 area by sometime Monday. News or analyst commentary could, of course, change the trading dynamics, but hopefully, if it occurs, it will be positive and produce a greater bounce.
Careful when reading the PR, they always engage in puffary and revenue recignition. Nobody cares about how they recognize cash already received to make earnings look better than reality, just tell us about new cash coming in.
I fear we may hear more about monetization of Kadcyla revenues. Other than selling the company, which they don't seem interested in doing, they are likely to pull this BS lever and cause more harm to the shareholders. More cash is needed in the next 6-12 months and unless they hit a homerun with some unexpected new data...they could choose to monetize. The problem with this is the loan shark rates the lenders charge. Terrible leadership, reckless, absent BOD. They need to cut costs yesterday!
I thought earnings were after hours, I was going to sell half before the close to be safe, holy #$%$ I got lucky for once!
Sentiment: Strong Buy